China reduces epilepsy seizures by 92.6% in first human chemogenetic trial
A new clinical trial in China successfully reduced seizures by 92.6% using a chemogenetic approach for patients with refractory epilepsy.
A new clinical trial in China successfully reduced seizures by 92.6% using a chemogenetic approach for patients with refractory epilepsy.